Education
About Us
Working with TipRanks
Follow Us
Ligand Pharma (LGND)
NASDAQ:LGND
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.43Last Year’s EPS
1.4Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 6.51%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with significant revenue growth and successful product launches. Despite challenges in the biopharmaceutical financing environment and a decline in Kyprolis sales, Ligand's diversified portfolio and strategic investments provide a positive outlook for the future.Company Guidance
During Ligand's first quarter 2025 earnings call, the company emphasized its strong start to the year, highlighting a 46% increase in total revenue compared to the same period last year. Royalty revenue saw a 44% growth, contributing $27.5 million, driven by successful performances from key products like Verona's Ohtuvayre and Merck's Capvaxive. Ligand maintained a robust financial position with over $209 million in cash and investments, and no debt, while also deploying nearly $250 million in capital across 10 investments over the past 15 months. The company reaffirmed its 2025 guidance, projecting royalty revenue between $135 million and $140 million and adjusted EPS between $6 and $6.25. CEO Todd Davis expressed optimism about the ongoing momentum from their royalty portfolio, including recent FDA approvals and strategic investments, which are expected to drive substantial growth and shareholder value through the year and beyond.Significant Revenue Growth
Ligand reported a 46% increase in total revenue for Q1 2025 compared to the same period last year, totaling just over $45 million. Royalty revenue grew by 44%, reaching $27.5 million.
Strong Financial Position
Ligand has over $200 million in cash and investments, no debt, and access to a $125 million revolving credit facility, which can be upsized to $200 million.
Successful Launches and Approvals
Verona Pharma's Ohtuvayre reported net sales of $71 million, and Merck's Capvaxive reported $107 million in sales, both exceeding expectations. Travere's Filspari is also seeing strong growth with a 180% year-over-year increase in sales.
Portfolio Diversification and Expansion
Ligand's portfolio consists of more than 90 assets diversified across various stages of clinical development and therapeutic areas. The company executed a strategic transaction with Channel Therapeutics to accelerate the commercialization of Zelsuvmi.
Positive Long-term Growth Outlook
Ligand expects a compound annual growth rate of 22% for royalty revenue by 2029, with current portfolio supporting an 18% CAGR.
LGND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LGND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $105.62 | $102.51 | -2.94% |
Feb 27, 2025 | $115.01 | $115.67 | +0.57% |
Nov 07, 2024 | $116.90 | $129.90 | +11.12% |
Aug 06, 2024 | $99.04 | $93.32 | -5.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ligand Pharma (LGND) report earnings?
Ligand Pharma (LGND) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Ligand Pharma (LGND) earnings time?
Ligand Pharma (LGND) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LGND EPS forecast?
LGND EPS forecast for the fiscal quarter 2025 (Q2) is 1.43.